AbCellera Biologics (HAM:8QQ) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:8QQ AbCellera Biologics Inc HAM:8QQ
61 GF Score
Price €4.82
GF Value €4.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AbCellera Biologics FFO per Share?

FFO per Share only applies to REITs.

HAM:8QQ
61GF Score
AbCellera Biologics Inc HAM:8QQ
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbCellera Biologics (HAM:8QQ) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of €4.82 is trading 2.6% above its estimated GF Value™ of €4.70. GuruFocus considers AbCellera Biologics to be Fairly Valued.

Key valuation signals for HAM:8QQ:

  • FFO per Share:
  • GF Value™: €4.70 vs. price of €4.82 (2.6% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the HAM:8QQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges ABCL:USA
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
61GF Score

Get the complete analysis for HAM:8QQ

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.82
Price
€4.70
GF Value